OLMIVIN AMH 20/5/12.5 — Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tablets

Overview

OLMIVIN AMH 20/5/12.5 is a triple-combination antihypertensive tablet that combines Olmesartan Medoxomil 20 mg, Amlodipine 5 mg, and Hydrochlorothiazide 12.5 mg. This formulation is specifically designed for patients whose blood pressure is not adequately controlled by monotherapy or dual therapy, offering potent and comprehensive blood pressure management.

By targeting three different mechanisms, OLMIVIN AMH provides effective hypertension control, reducing the risk of heart attack, stroke, and kidney complications.

Composition

Each tablet contains:

• Olmesartan Medoxomil 20 mg – Angiotensin II receptor blocker that relaxes blood vessels, lowering blood pressure.

• Amlodipine 5 mg – Calcium channel blocker that relaxes blood vessels and improves blood flow.

• Hydrochlorothiazide 12.5 mg – Thiazide diuretic that reduces fluid retention, decreasing blood volume and pressure.

(Excipients q.s., as per approved formulation.)

Dosage Form

• Tablet

Therapeutic Class

• Antihypertensive / Triple Combination Therapy

Indications

OLMIVIN AMH 20/5/12.5 Tablets are indicated for:

• Management of hypertension (high blood pressure)

• Patients requiring triple therapy for optimal blood pressure control

• Reduction of cardiovascular risk in patients with persistent hypertension

• Prevention of hypertension-related complications, including heart attack, stroke, and kidney damage

Mechanism of Action

• Olmesartan Medoxomil blocks the angiotensin II receptor, causing vasodilation and reducing aldosterone-mediated sodium retention.

• Amlodipine inhibits calcium influx in vascular smooth muscles, relaxing blood vessels and lowering vascular resistance.

• Hydrochlorothiazide increases urinary excretion of sodium and water, reducing blood volume and pressure.

• Together, the triple combination provides synergistic blood pressure control by addressing vascular resistance, fluid volume, and hormonal regulation.

Dosage and Administration

• Recommended Dose: As prescribed by the physician, usually once daily

• Route: Oral

• Duration: Long-term therapy as advised by a healthcare provider

Note: Regular monitoring of blood pressure, electrolytes, and kidney function is recommended during therapy.

Benefits

• Provides comprehensive blood pressure control

• Reduces risk of heart attack, stroke, and kidney disease

• Targets three different pathways for effective hypertension management

• Convenient once-daily tablet improves patient adherence

• Suitable for patients uncontrolled by monotherapy or dual therapy

Side Effects

OLMIVIN AMH 20/5/12.5 is generally well tolerated. Possible side effects include:

• Dizziness or lightheadedness

• Swelling of ankles or feet

• Mild gastrointestinal discomfort

• Electrolyte imbalances (rare)

• Fatigue

Consult your physician if side effects persist or worsen.

Precautions

• Use with caution in renal or liver impairment

• Avoid during pregnancy or lactation unless prescribed

• Inform your doctor about other medications to prevent drug interactions

• Regular monitoring of blood pressure, kidney function, and electrolytes is advised

Storage

Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.

Key Product Information

• Brand Name: OLMIVIN AMH 20/5/12.5

• Composition: Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg

• Dosage Form: Tablet

• Therapeutic Class: Antihypertensive / Triple Combination Therapy

• Manufacturer: [Insert Company Name]

• Packaging: [Example: 10×10 Tablets / Strip]

Why Choose OLMIVIN AMH 20/5/12.5

• Provides potent, triple-action blood pressure control

• Reduces cardiovascular and renal risks associated with hypertension

• Convenient once-daily dosing enhances compliance

• Manufactured under strict GMP-certified quality standards

Conclusion

OLMIVIN AMH 20/5/12.5 (Olmesartan Medoxomil 20 mg + Amlodipine 5 mg + Hydrochlorothiazide 12.5 mg Tablets) delivers comprehensive blood pressure management for patients with resistant or uncontrolled hypertension. By targeting vascular resistance, fluid retention, and hormonal regulation, it helps prevent cardiovascular and renal complications while supporting long-term heart health.